VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study

Robert Metcalf; S. Laban; C. A. Kristensen; T-E. Ciuleanu; I. Braña; A. Soria Rivas; S. M. Dieter; A. Bols; M. D. Forster; M. R. Covela; J. Christian; F. D. Vogl; C. Mueller; F. Triebel

doi:10.1016/j.annonc.2024.06.012

VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study

Robert Metcalf
, S. Laban
, C. A. Kristensen
, T-E. Ciuleanu
, I. Braña
, A. Soria Rivas
, S. M. Dieter
, A. Bols
, M. D. Forster
, M. R. Covela
, J. Christian
, F. D. Vogl
, C. Mueller
, F. Triebel

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Meeting Abstract

Abstract

Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.

Original language	English
Journal	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Volume	35
Issue number	8
DOIs	https://doi.org/10.1016/j.annonc.2024.06.012
Publication status	Published - 11 Jul 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2024.06.012

Fingerprint

Dive into the research topics of 'VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study'. Together they form a unique fingerprint.

Cite this

Metcalf, R., Laban, S., Kristensen, C. A., Ciuleanu, T.-E., Braña, I., Soria Rivas, A., Dieter, S. M., Bols, A., Forster, M. D., Covela, M. R., Christian, J., Vogl, F. D., Mueller, C., & Triebel, F. (2024). VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 35(8). https://doi.org/10.1016/j.annonc.2024.06.012

Metcalf, Robert ; Laban, S. ; Kristensen, C. A. et al. / VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2024 ; Vol. 35, No. 8.

@article{9930dadb6d3742e0ae24758700be77cf,

title = "VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study",

abstract = "Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation \& T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.",

author = "Robert Metcalf and S. Laban and Kristensen, \{C. A.\} and T-E. Ciuleanu and I. Bra{\~n}a and \{Soria Rivas\}, A. and Dieter, \{S. M.\} and A. Bols and Forster, \{M. D.\} and Covela, \{M. R.\} and J. Christian and Vogl, \{F. D.\} and C. Mueller and F. Triebel",

year = "2024",

month = jul,

day = "11",

doi = "10.1016/j.annonc.2024.06.012",

language = "English",

volume = "35",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "0923-7534",

publisher = "Elsevier BV",

number = "8",

}

Metcalf, R, Laban, S, Kristensen, CA, Ciuleanu, T-E, Braña, I, Soria Rivas, A, Dieter, SM, Bols, A, Forster, MD, Covela, MR, Christian, J, Vogl, FD, Mueller, C & Triebel, F 2024, 'VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study', Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, vol. 35, no. 8. https://doi.org/10.1016/j.annonc.2024.06.012

VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. / Metcalf, Robert; Laban, S.; Kristensen, C. A. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Vol. 35, No. 8, 11.07.2024.

Research output: Contribution to journal › Meeting Abstract

TY - JOUR

T1 - VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study

AU - Metcalf, Robert

AU - Laban, S.

AU - Kristensen, C. A.

AU - Ciuleanu, T-E.

AU - Braña, I.

AU - Soria Rivas, A.

AU - Dieter, S. M.

AU - Bols, A.

AU - Forster, M. D.

AU - Covela, M. R.

AU - Christian, J.

AU - Vogl, F. D.

AU - Mueller, C.

AU - Triebel, F.

PY - 2024/7/11

Y1 - 2024/7/11

N2 - Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.

AB - Eftilagimod alpha (E) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell activation & T-cell (CD4/CD8) recruitment/activation. Previous results from a phase II study of E plus pembrolizumab (P) as a second line therapy in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) resulted in promising response rates across all PD-L1 strata (TACTI-002; NCT03625323). We report results from the primary analysis of the first-line (1L) R/M HNSCC PD-L1 CPS negative Cohort B of the TACTI-003 study.

U2 - 10.1016/j.annonc.2024.06.012

DO - 10.1016/j.annonc.2024.06.012

M3 - Meeting Abstract

SN - 0923-7534

VL - 35

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 8

ER -

Metcalf R, Laban S, Kristensen CA, Ciuleanu TE, Braña I, Soria Rivas A et al. VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2024 Jul 11;35(8). doi: 10.1016/j.annonc.2024.06.012